APO Research
Talk to an analyst

APO RESEARCH · REPORT

HIV and AIDS Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global HIV and AIDS Vaccine Market Analysis and Forecast 2026-2032

27 December 2025192 pages

Choose your research edition.

Industry ResearchHIV and AIDS Vaccine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal HIV and AIDS Vaccine Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal HIV and AIDS Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal HIV and AIDS Vaccine Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal HIV and AIDS Vaccine Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global HIV and AIDS Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for HIV and AIDS Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for HIV and AIDS Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for HIV and AIDS Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for HIV and AIDS Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of HIV and AIDS Vaccine include HKUMed, Sanofi-Pasteur, Johnson and Johnson (Janssen), IAVI, Uvax Bio and AELIX Therapeutics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for HIV and AIDS Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of HIV and AIDS Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for HIV and AIDS Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the HIV and AIDS Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global HIV and AIDS Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for HIV and AIDS Vaccine sales, projected growth trends, production technology, application and end-user industry.

HIV and AIDS Vaccine Segment by Company

HKUMed

Sanofi-Pasteur

Johnson and Johnson (Janssen)

IAVI

Uvax Bio

AELIX Therapeutics

HIV and AIDS Vaccine Segment by Type

Preventive Vaccine

Therapeutic Vaccine

HIV and AIDS Vaccine Segment by Application

Viral Vector Vaccines

Nucleic Acid Vaccines (including mRNA Vaccines)

Recombinant Protein Vaccines

Other Vaccines

HIV and AIDS Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV and AIDS Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of HIV and AIDS Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV and AIDS Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of HIV and AIDS Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of HIV and AIDS Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, HIV and AIDS Vaccine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global HIV and AIDS Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Preventive Vaccine Major Manufacturers Table 3. Therapeutic Vaccine Major Manufacturers Table 4. Global HIV and AIDS Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Viral Vector Vaccines Major Manufacturers Table 6. Nucleic Acid Vaccines (including mRNA Vaccines) Major Manufacturers Table 7. Recombinant Protein Vaccines Major Manufacturers Table 8. Other Vaccines Major Manufacturers Table 9. HIV and AIDS Vaccine Industry Trends Table 10. HIV and AIDS Vaccine Industry Drivers Table 11. HIV and AIDS Vaccine Industry Opportunities and Challenges Table 12. HIV and AIDS Vaccine Industry Restraints Table 13. Global HIV and AIDS Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global HIV and AIDS Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 15. Global HIV and AIDS Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 16. Global HIV and AIDS Vaccine Revenue Market Share by Region (2021-2026) Table 17. Global HIV and AIDS Vaccine Revenue Market Share by Region (2027-2032) Table 18. Global HIV and AIDS Vaccine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 19. Global HIV and AIDS Vaccine Sales by Region (2021-2026) & (K Units) Table 20. Global HIV and AIDS Vaccine Sales by Region (2027-2032) & (K Units) Table 21. Global HIV and AIDS Vaccine Sales Market Share by Region (2021-2026) Table 22. Global HIV and AIDS Vaccine Sales Market Share by Region (2027-2032) Table 23. Global HIV and AIDS Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global HIV and AIDS Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 25. Global HIV and AIDS Vaccine Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global HIV and AIDS Vaccine Sales Market Share by Manufacturers (2021-2026) Table 27. Global HIV and AIDS Vaccine Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 28. Global HIV and AIDS Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global HIV and AIDS Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global HIV and AIDS Vaccine Manufacturers, Product Type & Application Table 31. Global HIV and AIDS Vaccine Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global HIV and AIDS Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global HIV and AIDS Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global HIV and AIDS Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 36. Global HIV and AIDS Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 37. Global HIV and AIDS Vaccine Revenue Market Share by Type (2021-2026) Table 38. Global HIV and AIDS Vaccine Revenue Market Share by Type (2027-2032) Table 39. Global HIV and AIDS Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 40. Global HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units) Table 41. Global HIV and AIDS Vaccine Sales by Type (2027-2032) & (K Units) Table 42. Global HIV and AIDS Vaccine Sales Market Share by Type (2021-2026) Table 43. Global HIV and AIDS Vaccine Sales Market Share by Type (2027-2032) Table 44. Global HIV and AIDS Vaccine Price by Type (2021-2026) & (US$/Unit) Table 45. Global HIV and AIDS Vaccine Price by Type (2027-2032) & (US$/Unit) Table 46. Global HIV and AIDS Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global HIV and AIDS Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 48. Global HIV and AIDS Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 49. Global HIV and AIDS Vaccine Revenue Market Share by Application (2021-2026) Table 50. Global HIV and AIDS Vaccine Revenue Market Share by Application (2027-2032) Table 51. Global HIV and AIDS Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 52. Global HIV and AIDS Vaccine Sales by Application (2021-2026) & (K Units) Table 53. Global HIV and AIDS Vaccine Sales by Application (2027-2032) & (K Units) Table 54. Global HIV and AIDS Vaccine Sales Market Share by Application (2021-2026) Table 55. Global HIV and AIDS Vaccine Sales Market Share by Application (2027-2032) Table 56. Global HIV and AIDS Vaccine Price by Application (2021-2026) & (US$/Unit) Table 57. Global HIV and AIDS Vaccine Price by Application (2027-2032) & (US$/Unit) Table 58. HKUMed Company Information Table 59. HKUMed Business Overview Table 60. HKUMed HIV and AIDS Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. HKUMed HIV and AIDS Vaccine Product Portfolio Table 62. HKUMed Recent Development Table 63. Sanofi-Pasteur Company Information Table 64. Sanofi-Pasteur Business Overview Table 65. Sanofi-Pasteur HIV and AIDS Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Sanofi-Pasteur HIV and AIDS Vaccine Product Portfolio Table 67. Sanofi-Pasteur Recent Development Table 68. Johnson and Johnson (Janssen) Company Information Table 69. Johnson and Johnson (Janssen) Business Overview Table 70. Johnson and Johnson (Janssen) HIV and AIDS Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Johnson and Johnson (Janssen) HIV and AIDS Vaccine Product Portfolio Table 72. Johnson and Johnson (Janssen) Recent Development Table 73. IAVI Company Information Table 74. IAVI Business Overview Table 75. IAVI HIV and AIDS Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. IAVI HIV and AIDS Vaccine Product Portfolio Table 77. IAVI Recent Development Table 78. Uvax Bio Company Information Table 79. Uvax Bio Business Overview Table 80. Uvax Bio HIV and AIDS Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Uvax Bio HIV and AIDS Vaccine Product Portfolio Table 82. Uvax Bio Recent Development Table 83. AELIX Therapeutics Company Information Table 84. AELIX Therapeutics Business Overview Table 85. AELIX Therapeutics HIV and AIDS Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. AELIX Therapeutics HIV and AIDS Vaccine Product Portfolio Table 87. AELIX Therapeutics Recent Development Table 88. North America HIV and AIDS Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 89. North America HIV and AIDS Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 90. North America HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units) Table 91. North America HIV and AIDS Vaccine Sales by Type (2027-2032) & (K Units) Table 92. North America HIV and AIDS Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 93. North America HIV and AIDS Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 94. North America HIV and AIDS Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 95. North America HIV and AIDS Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 96. North America HIV and AIDS Vaccine Sales by Application (2021-2026) & (K Units) Table 97. North America HIV and AIDS Vaccine Sales by Application (2027-2032) & (K Units) Table 98. North America HIV and AIDS Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 99. North America HIV and AIDS Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 100. North America HIV and AIDS Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. North America HIV and AIDS Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 102. North America HIV and AIDS Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 103. North America HIV and AIDS Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 104. North America HIV and AIDS Vaccine Sales by Country (2021-2026) & (K Units) Table 105. North America HIV and AIDS Vaccine Sales by Country (2027-2032) & (K Units) Table 106. North America HIV and AIDS Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 107. North America HIV and AIDS Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 108. United States HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 109. Canada HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 110. Mexico HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 111. Europe HIV and AIDS Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 112. Europe HIV and AIDS Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 113. Europe HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units) Table 114. Europe HIV and AIDS Vaccine Sales by Type (2027-2032) & (K Units) Table 115. Europe HIV and AIDS Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 116. Europe HIV and AIDS Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 117. Europe HIV and AIDS Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 118. Europe HIV and AIDS Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 119. Europe HIV and AIDS Vaccine Sales by Application (2021-2026) & (K Units) Table 120. Europe HIV and AIDS Vaccine Sales by Application (2027-2032) & (K Units) Table 121. Europe HIV and AIDS Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 122. Europe HIV and AIDS Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 123. Europe HIV and AIDS Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 124. Europe HIV and AIDS Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 125. Europe HIV and AIDS Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 126. Europe HIV and AIDS Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 127. Europe HIV and AIDS Vaccine Sales by Country (2021-2026) & (K Units) Table 128. Europe HIV and AIDS Vaccine Sales by Country (2027-2032) & (K Units) Table 129. Europe HIV and AIDS Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 130. Europe HIV and AIDS Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 131. Germany HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 132. France HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 133. U.K. HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 134. Italy HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 135. Russia HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 136. Spain HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 137. Netherlands HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 138. Switzerland HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 139. Sweden HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 140. Poland HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 141. China HIV and AIDS Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 142. China HIV and AIDS Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 143. China HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units) Table 144. China HIV and AIDS Vaccine Sales by Type (2027-2032) & (K Units) Table 145. China HIV and AIDS Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 146. China HIV and AIDS Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 147. China HIV and AIDS Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 148. China HIV and AIDS Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 149. China HIV and AIDS Vaccine Sales by Application (2021-2026) & (K Units) Table 150. China HIV and AIDS Vaccine Sales by Application (2027-2032) & (K Units) Table 151. China HIV and AIDS Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 152. China HIV and AIDS Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 153. Asia HIV and AIDS Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 154. Asia HIV and AIDS Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 155. Asia HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units) Table 156. Asia HIV and AIDS Vaccine Sales by Type (2027-2032) & (K Units) Table 157. Asia HIV and AIDS Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 158. Asia HIV and AIDS Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 159. Asia HIV and AIDS Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 160. Asia HIV and AIDS Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 161. Asia HIV and AIDS Vaccine Sales by Application (2021-2026) & (K Units) Table 162. Asia HIV and AIDS Vaccine Sales by Application (2027-2032) & (K Units) Table 163. Asia HIV and AIDS Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 164. Asia HIV and AIDS Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 165. Asia HIV and AIDS Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 166. Asia HIV and AIDS Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 167. Asia HIV and AIDS Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 168. Asia HIV and AIDS Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 169. Asia HIV and AIDS Vaccine Sales by Country (2021-2026) & (K Units) Table 170. Asia HIV and AIDS Vaccine Sales by Country (2027-2032) & (K Units) Table 171. Asia HIV and AIDS Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 172. Asia HIV and AIDS Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 173. Japan HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 174. South Korea HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 175. India HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 176. Australia HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 177. Taiwan HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 178. Southeast Asia HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 179. SAMEA HIV and AIDS Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 180. SAMEA HIV and AIDS Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 181. SAMEA HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units) Table 182. SAMEA HIV and AIDS Vaccine Sales by Type (2027-2032) & (K Units) Table 183. SAMEA HIV and AIDS Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 184. SAMEA HIV and AIDS Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 185. SAMEA HIV and AIDS Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 186. SAMEA HIV and AIDS Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 187. SAMEA HIV and AIDS Vaccine Sales by Application (2021-2026) & (K Units) Table 188. SAMEA HIV and AIDS Vaccine Sales by Application (2027-2032) & (K Units) Table 189. SAMEA HIV and AIDS Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 190. SAMEA HIV and AIDS Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 191. SAMEA HIV and AIDS Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 192. SAMEA HIV and AIDS Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 193. SAMEA HIV and AIDS Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 194. SAMEA HIV and AIDS Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 195. SAMEA HIV and AIDS Vaccine Sales by Country (2021-2026) & (K Units) Table 196. SAMEA HIV and AIDS Vaccine Sales by Country (2027-2032) & (K Units) Table 197. SAMEA HIV and AIDS Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 198. SAMEA HIV and AIDS Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 199. Brazil HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 200. Argentina HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 201. Chile HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 202. Colombia HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 203. Peru HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 204. Saudi Arabia HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 205. Israel HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 206. UAE HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 207. Turkey HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 208. Iran HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 209. Egypt HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Table 210. Key Raw Materials Table 211. Raw Materials Key Suppliers Table 212. HIV and AIDS Vaccine Distributors List Table 213. HIV and AIDS Vaccine Customers List Table 214. Research Programs/Design for This Report Table 215. Authors List of This Report Table 216. Secondary Sources Table 217. Primary Sources List of Figures Figure 1. HIV and AIDS Vaccine Image Figure 2. Global HIV and AIDS Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global HIV and AIDS Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Preventive Vaccine Image Figure 5. Therapeutic Vaccine Image Figure 6. Global HIV and AIDS Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global HIV and AIDS Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 8. Viral Vector Vaccines Image Figure 9. Nucleic Acid Vaccines (including mRNA Vaccines) Image Figure 10. Recombinant Protein Vaccines Image Figure 11. Other Vaccines Image Figure 12. Global HIV and AIDS Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global HIV and AIDS Vaccine Revenue (2021-2032) & (US$ Million) Figure 14. Global HIV and AIDS Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global HIV and AIDS Vaccine Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global HIV and AIDS Vaccine Revenue Market Share by Region (2021-2032) Figure 17. Global HIV and AIDS Vaccine Sales (2021-2032) & (K Units) Figure 18. Global HIV and AIDS Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 19. Global HIV and AIDS Vaccine Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico HIV and AIDS Vaccine Sales YoY (2021-2032) & (K Units) Figure 21. Europe HIV and AIDS Vaccine Sales YoY (2021-2032) & (K Units) Figure 22. China HIV and AIDS Vaccine Sales YoY (2021-2032) & (K Units) Figure 23. Asia (Excluding China) HIV and AIDS Vaccine Sales YoY (2021-2032) & (K Units) Figure 24. South America, Middle East and Africa HIV and AIDS Vaccine Sales YoY (2021-2032) & (K Units) Figure 25. Global HIV and AIDS Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global HIV and AIDS Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global HIV and AIDS Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global HIV and AIDS Vaccine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global HIV and AIDS Vaccine Revenue Market Share by Type (2021-2032) Figure 31. Global HIV and AIDS Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 32. Global HIV and AIDS Vaccine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global HIV and AIDS Vaccine Sales Market Share by Type (2021-2032) Figure 34. Global HIV and AIDS Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global HIV and AIDS Vaccine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global HIV and AIDS Vaccine Revenue Market Share by Application (2021-2032) Figure 37. Global HIV and AIDS Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 38. Global HIV and AIDS Vaccine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global HIV and AIDS Vaccine Sales Market Share by Application (2021-2032) Figure 40. North America HIV and AIDS Vaccine Revenue Share by Type (2021-2032) Figure 41. North America HIV and AIDS Vaccine Sales Share by Type (2021-2032) Figure 42. North America HIV and AIDS Vaccine Revenue Share by Application (2021-2032) Figure 43. North America HIV and AIDS Vaccine Sales Share by Application (2021-2032) Figure 44. North America HIV and AIDS Vaccine Revenue Share by Country (2021-2032) Figure 45. North America HIV and AIDS Vaccine Sales Share by Country (2021-2032) Figure 46. Europe HIV and AIDS Vaccine Revenue Share by Type (2021-2032) Figure 47. Europe HIV and AIDS Vaccine Sales Share by Type (2021-2032) Figure 48. Europe HIV and AIDS Vaccine Revenue Share by Application (2021-2032) Figure 49. Europe HIV and AIDS Vaccine Sales Share by Application (2021-2032) Figure 50. Europe HIV and AIDS Vaccine Revenue Share by Country (2021-2032) Figure 51. Europe HIV and AIDS Vaccine Sales Share by Country (2021-2032) Figure 52. China HIV and AIDS Vaccine Revenue Share by Type (2021-2032) Figure 53. China HIV and AIDS Vaccine Sales Share by Type (2021-2032) Figure 54. China HIV and AIDS Vaccine Revenue Share by Application (2021-2032) Figure 55. China HIV and AIDS Vaccine Sales Share by Application (2021-2032) Figure 56. Asia HIV and AIDS Vaccine Revenue Share by Type (2021-2032) Figure 57. Asia HIV and AIDS Vaccine Sales Share by Type (2021-2032) Figure 58. Asia HIV and AIDS Vaccine Revenue Share by Application (2021-2032) Figure 59. Asia HIV and AIDS Vaccine Sales Share by Application (2021-2032) Figure 60. Asia HIV and AIDS Vaccine Revenue Share by Country (2021-2032) Figure 61. Asia HIV and AIDS Vaccine Sales Share by Country (2021-2032) Figure 62. SAMEA HIV and AIDS Vaccine Revenue Share by Type (2021-2032) Figure 63. SAMEA HIV and AIDS Vaccine Sales Share by Type (2021-2032) Figure 64. SAMEA HIV and AIDS Vaccine Revenue Share by Application (2021-2032) Figure 65. SAMEA HIV and AIDS Vaccine Sales Share by Application (2021-2032) Figure 66. SAMEA HIV and AIDS Vaccine Revenue Share by Country (2021-2032) Figure 67. SAMEA HIV and AIDS Vaccine Sales Share by Country (2021-2032) Figure 68. HIV and AIDS Vaccine Value Chain Figure 69. Manufacturing Cost Structure Figure 70. HIV and AIDS Vaccine Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Preventive Vaccine
  • Therapeutic Vaccine
Applications
  • Viral Vector Vaccines
  • Nucleic Acid Vaccines (including mRNA Vaccines)
  • Recombinant Protein Vaccines
  • Other Vaccines
Companies covered
  • HKUMed
  • Sanofi-Pasteur
  • Johnson and Johnson (Janssen)
  • IAVI
  • Uvax Bio
  • AELIX Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 HIV and AIDS Vaccine Market by Type
  3. 1.2.1 Global HIV and AIDS Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Preventive Vaccine
  5. 1.2.3 Therapeutic Vaccine
  6. 1.3 HIV and AIDS Vaccine Market by Application
  7. 1.3.1 Global HIV and AIDS Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Viral Vector Vaccines
  9. 1.3.3 Nucleic Acid Vaccines (including mRNA Vaccines)
  10. 1.3.4 Recombinant Protein Vaccines
  11. 1.3.5 Other Vaccines
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 HIV and AIDS Vaccine Market Dynamics
  1. 2.1 HIV and AIDS Vaccine Industry Trends
  2. 2.2 HIV and AIDS Vaccine Industry Drivers
  3. 2.3 HIV and AIDS Vaccine Industry Opportunities and Challenges
  4. 2.4 HIV and AIDS Vaccine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global HIV and AIDS Vaccine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global HIV and AIDS Vaccine Revenue by Region
  3. 3.2.1 Global HIV and AIDS Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global HIV and AIDS Vaccine Revenue by Region (2021-2026)
  5. 3.2.3 Global HIV and AIDS Vaccine Revenue by Region (2027-2032)
  6. 3.2.4 Global HIV and AIDS Vaccine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global HIV and AIDS Vaccine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global HIV and AIDS Vaccine Sales by Region
  9. 3.4.1 Global HIV and AIDS Vaccine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global HIV and AIDS Vaccine Sales by Region (2021-2026)
  11. 3.4.3 Global HIV and AIDS Vaccine Sales by Region (2027-2032)
  12. 3.4.4 Global HIV and AIDS Vaccine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global HIV and AIDS Vaccine Revenue by Manufacturers
  2. 4.1.1 Global HIV and AIDS Vaccine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global HIV and AIDS Vaccine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global HIV and AIDS Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global HIV and AIDS Vaccine Sales by Manufacturers
  6. 4.2.1 Global HIV and AIDS Vaccine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global HIV and AIDS Vaccine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global HIV and AIDS Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global HIV and AIDS Vaccine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global HIV and AIDS Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global HIV and AIDS Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global HIV and AIDS Vaccine Manufacturers, Product Type & Application
  13. 4.7 Global HIV and AIDS Vaccine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global HIV and AIDS Vaccine Market CR5 and HHI
  16. 4.8.2 2025 HIV and AIDS Vaccine Tier 1, Tier 2, and Tier 3
5 HIV and AIDS Vaccine Market by Type
  1. 5.1 Global HIV and AIDS Vaccine Revenue by Type
  2. 5.1.1 Global HIV and AIDS Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global HIV and AIDS Vaccine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global HIV and AIDS Vaccine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global HIV and AIDS Vaccine Sales by Type
  6. 5.2.1 Global HIV and AIDS Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global HIV and AIDS Vaccine Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global HIV and AIDS Vaccine Sales Market Share by Type (2021-2032)
  9. 5.3 Global HIV and AIDS Vaccine Price by Type
6 HIV and AIDS Vaccine Market by Application
  1. 6.1 Global HIV and AIDS Vaccine Revenue by Application
  2. 6.1.1 Global HIV and AIDS Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global HIV and AIDS Vaccine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global HIV and AIDS Vaccine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global HIV and AIDS Vaccine Sales by Application
  6. 6.2.1 Global HIV and AIDS Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global HIV and AIDS Vaccine Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global HIV and AIDS Vaccine Sales Market Share by Application (2021-2032)
  9. 6.3 Global HIV and AIDS Vaccine Price by Application
7 Company Profiles
  1. 7.1 HKUMed
  2. 7.1.1 HKUMed Company Information
  3. 7.1.2 HKUMed Business Overview
  4. 7.1.3 HKUMed HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 HKUMed HIV and AIDS Vaccine Product Portfolio
  6. 7.1.5 HKUMed Recent Developments
  7. 7.2 Sanofi-Pasteur
  8. 7.2.1 Sanofi-Pasteur Company Information
  9. 7.2.2 Sanofi-Pasteur Business Overview
  10. 7.2.3 Sanofi-Pasteur HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi-Pasteur HIV and AIDS Vaccine Product Portfolio
  12. 7.2.5 Sanofi-Pasteur Recent Developments
  13. 7.3 Johnson and Johnson (Janssen)
  14. 7.3.1 Johnson and Johnson (Janssen) Company Information
  15. 7.3.2 Johnson and Johnson (Janssen) Business Overview
  16. 7.3.3 Johnson and Johnson (Janssen) HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Johnson and Johnson (Janssen) HIV and AIDS Vaccine Product Portfolio
  18. 7.3.5 Johnson and Johnson (Janssen) Recent Developments
  19. 7.4 IAVI
  20. 7.4.1 IAVI Company Information
  21. 7.4.2 IAVI Business Overview
  22. 7.4.3 IAVI HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 IAVI HIV and AIDS Vaccine Product Portfolio
  24. 7.4.5 IAVI Recent Developments
  25. 7.5 Uvax Bio
  26. 7.5.1 Uvax Bio Company Information
  27. 7.5.2 Uvax Bio Business Overview
  28. 7.5.3 Uvax Bio HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Uvax Bio HIV and AIDS Vaccine Product Portfolio
  30. 7.5.5 Uvax Bio Recent Developments
  31. 7.6 AELIX Therapeutics
  32. 7.6.1 AELIX Therapeutics Company Information
  33. 7.6.2 AELIX Therapeutics Business Overview
  34. 7.6.3 AELIX Therapeutics HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 AELIX Therapeutics HIV and AIDS Vaccine Product Portfolio
  36. 7.6.5 AELIX Therapeutics Recent Developments
8 North America
  1. 8.1 North America HIV and AIDS Vaccine Market Size by Type
  2. 8.1.1 North America HIV and AIDS Vaccine Revenue by Type (2021-2032)
  3. 8.1.2 North America HIV and AIDS Vaccine Sales by Type (2021-2032)
  4. 8.1.3 North America HIV and AIDS Vaccine Price by Type (2021-2032)
  5. 8.2 North America HIV and AIDS Vaccine Market Size by Application
  6. 8.2.1 North America HIV and AIDS Vaccine Revenue by Application (2021-2032)
  7. 8.2.2 North America HIV and AIDS Vaccine Sales by Application (2021-2032)
  8. 8.2.3 North America HIV and AIDS Vaccine Price by Application (2021-2032)
  9. 8.3 North America HIV and AIDS Vaccine Market Size by Country
  10. 8.3.1 North America HIV and AIDS Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America HIV and AIDS Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America HIV and AIDS Vaccine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe HIV and AIDS Vaccine Market Size by Type
  2. 9.1.1 Europe HIV and AIDS Vaccine Revenue by Type (2021-2032)
  3. 9.1.2 Europe HIV and AIDS Vaccine Sales by Type (2021-2032)
  4. 9.1.3 Europe HIV and AIDS Vaccine Price by Type (2021-2032)
  5. 9.2 Europe HIV and AIDS Vaccine Market Size by Application
  6. 9.2.1 Europe HIV and AIDS Vaccine Revenue by Application (2021-2032)
  7. 9.2.2 Europe HIV and AIDS Vaccine Sales by Application (2021-2032)
  8. 9.2.3 Europe HIV and AIDS Vaccine Price by Application (2021-2032)
  9. 9.3 Europe HIV and AIDS Vaccine Market Size by Country
  10. 9.3.1 Europe HIV and AIDS Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe HIV and AIDS Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe HIV and AIDS Vaccine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China HIV and AIDS Vaccine Market Size by Type
  2. 10.1.1 China HIV and AIDS Vaccine Revenue by Type (2021-2032)
  3. 10.1.2 China HIV and AIDS Vaccine Sales by Type (2021-2032)
  4. 10.1.3 China HIV and AIDS Vaccine Price by Type (2021-2032)
  5. 10.2 China HIV and AIDS Vaccine Market Size by Application
  6. 10.2.1 China HIV and AIDS Vaccine Revenue by Application (2021-2032)
  7. 10.2.2 China HIV and AIDS Vaccine Sales by Application (2021-2032)
  8. 10.2.3 China HIV and AIDS Vaccine Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia HIV and AIDS Vaccine Market Size by Type
  2. 11.1.1 Asia HIV and AIDS Vaccine Revenue by Type (2021-2032)
  3. 11.1.2 Asia HIV and AIDS Vaccine Sales by Type (2021-2032)
  4. 11.1.3 Asia HIV and AIDS Vaccine Price by Type (2021-2032)
  5. 11.2 Asia HIV and AIDS Vaccine Market Size by Application
  6. 11.2.1 Asia HIV and AIDS Vaccine Revenue by Application (2021-2032)
  7. 11.2.2 Asia HIV and AIDS Vaccine Sales by Application (2021-2032)
  8. 11.2.3 Asia HIV and AIDS Vaccine Price by Application (2021-2032)
  9. 11.3 Asia HIV and AIDS Vaccine Market Size by Country
  10. 11.3.1 Asia HIV and AIDS Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia HIV and AIDS Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia HIV and AIDS Vaccine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA HIV and AIDS Vaccine Market Size by Type
  2. 12.1.1 SAMEA HIV and AIDS Vaccine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA HIV and AIDS Vaccine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA HIV and AIDS Vaccine Price by Type (2021-2032)
  5. 12.2 SAMEA HIV and AIDS Vaccine Market Size by Application
  6. 12.2.1 SAMEA HIV and AIDS Vaccine Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA HIV and AIDS Vaccine Sales by Application (2021-2032)
  8. 12.2.3 SAMEA HIV and AIDS Vaccine Price by Application (2021-2032)
  9. 12.3 SAMEA HIV and AIDS Vaccine Market Size by Country
  10. 12.3.1 SAMEA HIV and AIDS Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA HIV and AIDS Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA HIV and AIDS Vaccine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 HIV and AIDS Vaccine Value Chain Analysis
  2. 13.1.1 HIV and AIDS Vaccine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 HIV and AIDS Vaccine Production Mode & Process
  6. 13.2 HIV and AIDS Vaccine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 HIV and AIDS Vaccine Distributors
  9. 13.2.3 HIV and AIDS Vaccine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst